Citation Impact
32 standout
Citing Papers
Bispecific antibodies: advancing precision oncology
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Works of Iris To being referenced
Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL).
2021
Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts
2020
Author Peers
| Author | PFM | Genetics | Oncology | RNMI | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Iris To | 98 | 20 | 109 | 43 | 15 | 116 | |
| Michael Langsam | 2 | 2 | 23 | 687 | |||
| Ho-Fai Wong | 61 | 31 | 123 | 157 | 28 | 667 | |
| MA Hixon | 10 | 748 | |||||
| Carmen‐Pilar Martí‐Ballester | 1 | 31 | 616 | ||||
| Randi Nordström | 1 | 1 | 11 | 2 | 14 | 684 |
All Works
Loading papers...